darunavir has been researched along with tipranavir in 58 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (tipranavir) | Trials (tipranavir) | Recent Studies (post-2010) (tipranavir) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 289 | 42 | 47 |
| Protein | Taxonomy | darunavir (IC50) | tipranavir (IC50) |
|---|---|---|---|
| Protease | Human immunodeficiency virus 1 | 0.03 | |
| CAAX prenyl protease 1 homolog | Mus musculus (house mouse) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (48.28) | 29.6817 |
| 2010's | 28 (48.28) | 24.3611 |
| 2020's | 2 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB | 1 |
| Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P | 1 |
| Amano, M; Baldridge, A; Das, D; Davis, DA; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Matsumi, S; Mitsuya, H; Shioda, T; Yarchoan, R | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI | 1 |
| Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B | 1 |
| Andrews, KT; Butterworth, AS; Eickel, N; Gardiner, DL; MacDonald, T; McCarthy, JS; Peatey, CL; Skinner-Adams, TS; Trenholme, KR | 1 |
| Amano, M; Anderson, DD; Aoki, M; Das, D; Ghosh, AK; Koh, Y; Kulkarni, S; Mitsuya, H; Tojo, Y | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Cane, PA; Kolli, M; Myers, RE; Parry, CM; Pillay, D; Schiffer, C | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Nelson, MR; Waters, L | 1 |
| Dauer, B | 1 |
| Hill, A; Moyle, G | 1 |
| Gallant, JE; Hoffman, CJ | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Hall, D | 1 |
| Morales Conejo, M; Moreno Cuerda, VJ; Rubio García, R | 1 |
| Bacha, UM; Brower, ET; Freire, E; Kawasaki, Y | 1 |
| Choe, S; Corral, A; de Mendoza, C; García-Gasco, P; Parkin, N; Poveda, E; Soriano, V | 1 |
| Barber, T; Hughes, A; Nelson, M | 1 |
| Blanche, S; de Truchis, P; Delaugerre, C; Dominguez, S; Ghosn, J; Molina, JM; Mortier, E; Palmer, P; Pavie, J; Roudiere, L | 1 |
| Enejosa, J; Hinkle, J; Kearney, BP; Mack, R; Mathias, AA; Piliero, PJ; Sekar, V; Shen, G; Tomaka, F | 1 |
| Louis, JM; Sayer, JM | 1 |
| Cartledge, JD; Lascar, M | 1 |
| Kuhlmann, B | 1 |
| Castagna, A; Fusetti, G; Galli, L; Gianotti, N; Lazzarin, A; Salpietro, S; Seminari, E; Spagnuolo, V | 1 |
| Angarano, G; Monno, L; Saracino, A; Tartaglia, A; Tinelli, C | 1 |
| Backus, LI; Belperio, PS; Boothroyd, DB; Mole, LX | 1 |
| Barreiro, P; Fernández-Montero, JV; Soriano, V | 1 |
| Arribas, JR | 2 |
| Backus, LI; Belperio, PS; Boothroyd, DB; Mole, LA | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Berger, DS; Cheng, AK; Chuck, SL; Enejosa, JV; Kearney, BP; Lampiris, H; Zhong, L; Zolopa, AR | 1 |
| de Souza, DF; Diaz, RS; Inocencio, LA; Janini, LM; Munerato, P; Oliveros, MP; Pereira, AA; Sucupira, MC | 1 |
| Briz, V; de José, MI; González-Tomé, MI; León Leal, JA; Muñoz-Fernández, MA; Navarro, ML; Palladino, C; Ramos, JT | 1 |
| Baril, JG; Brenner, B; Cantin, R; Charest, H; Grant, P; Liu, TF; Roger, M; Shafer, R; Talbot, A; Taylor, J; Zolopa, A | 1 |
| Anta, L; Blanco, JL; Casado, JL; de Mendoza, C; García, F; Gómez-Sirvent, JL; Gutiérrez, F; Iribarren, JA; Poveda, E; Soriano, V | 1 |
| Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Aboulker, JP; Barrail-Tran, A; Braun, J; Charreau, I; de Castro, N; Delaugerre, C; Goldwirt, L; Lascoux-Combe, C; Molina, JM; Raffi, F; Taburet, AM | 1 |
| Álvarez-Tejado, M; Clotet, B; Codoñer, FM; Dalmau, D; Delgado, R; García, F; Paredes, R; Pou, C; Ruiz, L; Thielen, A | 1 |
| Aslanyan, S; Kohlbrenner, V; Kort, JJ; Robinson, P; Sabo, JP; Scherer, J | 1 |
| Brunzelle, JS; Dewdney, TG; Kovari, IA; Kovari, LC; Liu, Z; Reiter, SJ; Wang, Y | 1 |
| Nsanzabana, C; Rosenthal, PJ | 1 |
| Elgadi, MM; Piliero, PJ | 1 |
| Chang, SC; Chang, SY; Chen, MY; Hsieh, SM; Hung, CC; Sheng, WH | 1 |
| Bethell, R; Coakley, E; Hall, D; Paquet, A; Scherer, J; Witvrouw, M | 1 |
| Berhan, A; Berhan, Y | 1 |
| Castillero-Manzano, M; Escoto-Delgadillo, M; Flores-Soto, M; Gálvez-Gastelum, F; Mata-Munguía, C; Torres-Mendoza, B; Vázquez-Torres, M; Vázquez-Valls, E; Viniegra-Osorio, A | 1 |
| Aoki, M; Aoki-Ogata, H; Chang, SB; Das, D; Davis, DA; Desai, DV; Fyvie, WS; Garimella, H; Ghosh, AK; Kaufman, JD; Maeda, K; Mitsuya, H; Smith, DW; Wingfield, PT; Yedidi, RS | 1 |
| Raines, RT; Windsor, IW | 1 |
| Kranjc, A; Pietrucci, F; Vargiu, AV | 1 |
| Chávez-García, M; Domínguez-Hermosillo, JC; García-Gámez, JG; Gaytán-Martínez, JE; Herrera-González, NE; Huerta-García, G; Jiménez-Romero, A; Mata-Marin, JA; Nuñez-Rodríguez, N | 1 |
| Elhadad, H; Hien, NM; Huy, NT; Tam, DNH; Tran, L | 1 |
12 review(s) available for darunavir and tipranavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New drugs.
Topics: Anti-HIV Agents; Benzophenones; Cytidine Triphosphate; Darunavir; Deoxycytidine; Emtricitabine; HIV; HIV Fusion Inhibitors; HIV Reverse Transcriptase; Humans; Imidazoles; Nitriles; Protease Inhibitors; Pyridazines; Pyridines; Pyrimidines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Sulfur Compounds; Zalcitabine | 2005 |
Protease inhibitors: the current status.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Diarrhea; Dizziness; Drug Evaluation, Preclinical; Drug Therapy, Combination; Headache; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Pyridines; Pyrones; Sulfonamides; Treatment Outcome | 2005 |
When and how to use tipranavir and darunavir.
Topics: Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Interactions; HIV Infections; Humans; Pyridines; Pyrones; Sulfonamides; Viral Load | 2007 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
[New therapeutic options in protracted HIV-infected patients with virological failure].
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Organic Chemicals; Peptide Fragments; Practice Guidelines as Topic; Pyridines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; RNA, Viral; Sulfonamides | 2008 |
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome; Triazoles | 2008 |
New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Topics: Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Sulfonamides; Treatment Outcome | 2008 |
HIV protease inhibitors: recent clinical trials and recommendations on use.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Atazanavir Sulfate; Clinical Trials as Topic; Darunavir; Drug Interactions; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Metabolome; Oligopeptides; Pyridines; Pyrones; Sulfonamides; Treatment Outcome | 2009 |
[Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2008 |
Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Ritonavir; Sulfonamides | 2009 |
Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; HIV Infections; HIV-1; Humans; Odds Ratio; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
6 trial(s) available for darunavir and tipranavir
| Article | Year |
|---|---|
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Topics: Adult; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Pyridines; Pyrones; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
Topics: Adolescent; Adult; Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pyridines; Pyrones; Quinolones; Ritonavir; Sulfonamides | 2008 |
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pyridines; Pyrones; Quinolones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers.
Topics: Adult; Blood Coagulation; Blood Coagulation Factors; Darunavir; Drug Therapy, Combination; Female; Fibrinolysis; HIV Protease Inhibitors; Humans; Male; Middle Aged; Platelet Aggregation; Prospective Studies; Pyridines; Pyrones; Ritonavir; Sulfonamides | 2011 |
Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.
Topics: Adult; Darunavir; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Pyridines; Pyrones; Sulfonamides; Treatment Outcome; Viral Load | 2011 |
40 other study(ies) available for darunavir and tipranavir
| Article | Year |
|---|---|
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles | 2005 |
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Topics: Algorithms; Anti-Retroviral Agents; Benzodioxoles; Blood Proteins; Carbamates; Cell Line; Drug Resistance, Viral; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Orosomucoid; Phenotype; Serum; Serum Albumin; Tyrosine | 2007 |
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
Topics: Animals; CCR5 Receptor Antagonists; CD4 Antigens; Chlorocebus aethiops; COS Cells; Darunavir; Dimerization; Dose-Response Relationship, Drug; Enzyme Activation; Fluorescence Resonance Energy Transfer; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Protein Processing, Post-Translational; Pyridines; Pyrones; Receptors, CCR5; Sulfonamides; Virus Replication | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage | 2008 |
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides | 2008 |
Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.
Topics: Animals; Antimalarials; Darunavir; Erythrocytes; HIV Protease Inhibitors; Humans; Life Cycle Stages; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyridines; Pyrones; Sulfonamides | 2010 |
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Topics: Cell Line; Dimerization; Drug Resistance, Multiple, Viral; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Macrocyclic Compounds; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Virus Replication | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
Topics: Cell Line; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; gag Gene Products, Human Immunodeficiency Virus; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Virus Replication | 2011 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
Topics: Adolescent; Adult; Anti-HIV Agents; Clinical Trials, Phase IV as Topic; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Patient Selection; Pyridines; Pyrones; Research Design; Sulfonamides; Viral Load | 2007 |
Relative antiviral efficacy should not be inferred from cross-trial comparisons.
Topics: Cross-Over Studies; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Pyridines; Pyrones; Ritonavir; Sulfonamides; Treatment Outcome | 2007 |
Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; Hydrogen Bonding; Kinetics; Lopinavir; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Structure-Activity Relationship; Substrate Specificity; Sulfonamides | 2008 |
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
Topics: Chi-Square Distribution; Darunavir; Drug Resistance, Viral; Genes, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Logistic Models; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides | 2008 |
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Pyridines; Pyrones; Sulfonamides; Treatment Failure; Viral Load | 2008 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
[HIV therapy and adherence].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Oxazines; Patient Compliance; Prognosis; Pyridines; Pyrones; Sulfonamides | 2008 |
Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.
Topics: Darunavir; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyridines; Pyrones; Sulfonamides; Treatment Failure | 2009 |
Both a protective and a deleterious role for the L76V mutation.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyridines; Pyrimidinones; Pyrones; Sulfonamides | 2009 |
Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Darunavir; Enfuvirtide; Guideline Adherence; Guidelines as Topic; Health Plan Implementation; HIV Envelope Protein gp41; HIV Infections; Humans; Oligopeptides; Peptide Fragments; Practice Patterns, Physicians'; Pyridines; Pyrones; Retrospective Studies; Sulfonamides; Time Factors; United States; United States Department of Veterans Affairs | 2009 |
Trends in uptake of recently approved antiretrovirals within a national healthcare system.
Topics: Ambulatory Care Facilities; Anti-Retroviral Agents; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Approval; Drug Prescriptions; Electronic Health Records; Female; Health Facility Size; HIV Infections; Humans; Male; Oligopeptides; Practice Patterns, Physicians'; Pyridines; Pyrones; Retrospective Studies; Sulfonamides; Time Factors; United States; United States Food and Drug Administration; Veterans | 2010 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.
Topics: Alkynes; Benzoxazines; Brazil; Cohort Studies; Cyclopropanes; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
Topics: Adolescent; Child; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2010 |
Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.
Topics: Algorithms; Amino Acid Substitution; Cohort Studies; Darunavir; Databases, Factual; Drug Resistance, Multiple, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Multivariate Analysis; Mutation; Phenotype; Pyridines; Pyrones; Quebec; Sulfonamides | 2010 |
Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
Topics: Darunavir; Databases, Factual; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Pyridines; Pyrones; Spain; Sulfonamides | 2010 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
Topics: Anti-HIV Agents; Darunavir; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Peptide Fragments; Pyridines; Pyrones; Ritonavir; Sulfonamides | 2011 |
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Male; Mutation; Pyridines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Sulfonamides; Treatment Failure | 2011 |
The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.
Topics: Amino Acid Sequence; Darunavir; Drug Design; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Molecular Sequence Data; Mutation; Pyridines; Pyrones; Sulfonamides | 2011 |
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2011 |
Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Pyridines; Pyrones; Sulfonamides; Taiwan; Treatment Failure | 2011 |
Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
Topics: Adult; Algorithms; Darunavir; Drug Resistance, Viral; Female; Genetic Predisposition to Disease; Genotype; HIV Protease Inhibitors; Humans; Male; Mutation; Phenotype; Prevalence; Pyridines; Pyrones; San Francisco; Sulfonamides | 2012 |
Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Topics: Atazanavir Sulfate; Base Sequence; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Docking Simulation; Molecular Sequence Data; Mutation; Oligopeptides; Phenotype; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides | 2014 |
A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
Topics: Carbamates; Catalytic Domain; Crystallization; Darunavir; Drug Resistance, Multiple, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Molecular Conformation; Molecular Sequence Data; Protein Folding; Pyridines; Pyrones; Sulfonamides; X-Ray Diffraction | 2014 |
Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
Topics: Carbamates; Darunavir; Fluorescence; Fluorescent Dyes; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Pyridines; Pyrones; Sulfonamides | 2015 |
HIV-1 Protease Dimerization Dynamics Reveals a Transient Druggable Binding Pocket at the Interface.
Topics: Binding Sites; Crystallography, X-Ray; Darunavir; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Models, Molecular; Protein Binding; Protein Conformation; Protein Multimerization; Pyridines; Pyrones; Sulfonamides; Thermodynamics | 2015 |
Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Mexico; Middle Aged; Prospective Studies; Pyridines; Pyrones; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2016 |
Evaluation of COVID-19 protease and HIV inhibitors interactions.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; Darunavir; Humans; Lopinavir; Molecular Docking Simulation; Peptide Hydrolases; Protease Inhibitors | 2022 |